A Phase II Trial of IPH2101 (Anti-KIR) in Smoldering Multiple Myeloma (SMM).

Trial Profile

A Phase II Trial of IPH2101 (Anti-KIR) in Smoldering Multiple Myeloma (SMM).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Lirilumab (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 May 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 03 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 03 Jul 2012 Actual patient number is 9 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top